Advertisements

Ursidesox (Ursodiol)

Quick links to important sections

Ursidesox (Ursodiol)

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Ursidesox (Ursodiol)

Understanding Ursidesox (Ursodiol)

Ursidesox is a medication containing the active ingredient ursodiol, which is a naturally occurring bile acid. In the human body, bile acids are produced by the liver and stored in the gallbladder to assist in the digestion of fats. Ursodiol is often referred to as a hydrophilic (water-loving) bile acid, distinguishing it from other bile acids that can be more irritating to body tissues.

Mechanism of Action

Ursodiol works through several biological pathways to support liver and gallbladder health:

  • Cholesterol Reduction: It reduces the amount of cholesterol produced by the liver and absorbed by the intestines. By lowering the cholesterol saturation of bile, it helps prevent the formation of new cholesterol-based gallstones and may gradually facilitate the dissolution of existing ones.
  • Bile Flow Improvement: It promotes the flow of bile through the liver ducts, which can help prevent the buildup of toxic bile acids that might otherwise damage liver cells.
  • Cell Protection: It acts to protect liver cell membranes from the corrosive effects of more aggressive, hydrophobic bile acids.

Primary Uses

This medication is primarily utilized in the management of chronic cholestatic liver diseases. These are conditions where bile flow is restricted or stopped, potentially leading to liver scarring or inflammation. It is also used in specific cases involving gallbladder stones for patients who are not candidates for surgery or as a preventative measure during periods of rapid weight loss, which can increase the risk of stone formation.

Advertisements

What side effects are possible with Ursidesox (Ursodiol)?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential adverse effects of Ursodiol (Ursodeoxycholic acid) based on the system-organ class involved and the documented frequency of occurrence.

Frequency-Classified Adverse Reactions

The safety profile primarily involves Gastrointestinal disorders. The most frequently reported adverse effects are typically classified as Common (occurring in 1/100 to < 1/10 patients) and include diarrhoea or pasty stools. U.S. label data also documents headache and abdominal pain as having a high frequency in clinical trials.

Adverse reactions classified as Very Rare (< 1/10,000) include severe right upper abdominal pain, calcification of gallstones, and urticaria (hives). Certain effects, such as nausea, vomiting, and pruritus (itching), are documented but often categorized as Not Known due to insufficient data for reliable frequency estimation.

Serious Adverse Reactions and Safety Constraints

While rare, the official safety documentation highlights significant risks, particularly related to the Hepatobiliary disorders. In patients with advanced Primary Biliary Cholangitis (PBC), there is a very rare risk of decompensation of hepatic cirrhosis. Additionally, rare post-marketing reports include drug hypersensitivity reactions, such as angioedema.

Regulatory restrictions mandate that the medicine should not be used in individuals with a complete obstruction of the biliary tract or those with radio-opaque calcified gallstones. The label also requires regular monitoring of liver function parameters ( AST, ALT, gamma -GT, bilirubin) during therapy. Regarding timing, the regulatory text notes that in rare cases, pruritus may temporarily worsen at the beginning of treatment for PBC.

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Risks

Acute overdose with Ursodeoxycholic acid (Ursodiol) is primarily characterized by severe effects documented in the gastrointestinal system. The most common and formally described clinical manifestation listed in regulatory sources is severe diarrhea, which may be accompanied by abdominal pain.

The most significant risk following an acute oral overdose is not due to inherent systemic toxicity, but rather the potential for consequential complications arising from unmanaged gastrointestinal distress. Specifically, persistent and severe diarrhea can lead to clinically relevant dehydration and electrolyte imbalance, a scenario that requires immediate medical intervention for stabilization.


Emergency Actions and Management

Official regulatory guidance mandates specific actions be taken when an overdose is suspected. Individuals are instructed to seek immediate medical attention or contact emergency services upon the onset of severe symptoms, such as unresolving diarrhea.

The mandated management approach is symptomatic and supportive treatment. The essential therapeutic goal is the correction of fluid and electrolyte imbalance to mitigate the effects of severe fluid loss. Regulatory documentation explicitly confirms that no specific antidote is known for Ursodiol overdose. Continuous observation and hospital monitoring may be required, depending on the sustained severity of symptoms and the patient's state of hydration.

Advertisements

Therapeutic Uses of Ursidesox (Ursodiol)

What Ursidesox (Ursodiol) Treats: Main Uses and Benefits

Ursidesox (Ursodiol) is commonly used to treat conditions marked by increased physiological stress within the liver and biliary system, aiming to offer supportive therapeutic benefit. The medication plays a role in managing health domains related to biliary and liver function.

The medication is commonly used to help with long-term support for Primary Biliary Cholangitis (PBC), the management of cholesterol gallstones, and relief from cholestasis-related symptoms.

Long-Term Support for Primary Biliary Cholangitis (PBC)

Ursodiol is commonly used to manage Primary Biliary Cholangitis (PBC), a chronic liver disease affecting bile flow. This long-term therapy generally helps to slow the rate of disease progression, contributing to improved comfort during periods of heightened symptoms and supporting a sense of stability for patients. Its use in this context is relevant for chronic, stabilizing management.

Relief from Cholestasis-Related Symptoms

The drug supports patients by addressing the highly distressing symptoms that arise from impaired bile flow, collectively known as cholestasis. It is frequently applied to ease the intense, pervasive pruritus (itching) and may assist with managing biochemical markers, providing symptomatic relief that helps improve day-to-day comfort and stability. It is also relevant in specialized scenarios, such as managing Intrahepatic Cholestasis of Pregnancy (ICP).


Quick Fact: Primary Therapeutic Focus
Symptom Relieved Intense, generalized pruritus (itching)
Condition Context Chronic liver conditions (PBC) and Gallstone presence
Primary Benefit Supports stability and helps ease overall symptom burden
Advertisements

Eligibility and Restrictions for Use

The eligibility for Ursidesox (Ursodiol) is strictly defined by regulatory documents based on the patient's age and pre-existing clinical status. The medicine is primarily indicated for adults with Primary Biliary Cholangitis (PBC) and for the dissolution of certain radiolucent gallstones. For the pediatric population, established use is limited to children aged 6 to less than 18 years for hepatobiliary disorders associated with cystic fibrosis. Use in the general pediatric population for other conditions is often classified as not established.

Ursodiol is contraindicated and must not be used in specific populations. This includes patients with known hypersensitivity to the drug or those with absolute physical barriers, such as a complete biliary obstruction or radio-opaque calcified gallstones. It is also prohibited if the patient has acute inflammation of the biliary tract, frequent biliary colic, or inflammatory diseases of the small intestine or colon.

For pregnancy, regulatory guidance varies: European labeling classifies use as contraindicated, requiring women of childbearing potential to use reliable non-hormonal contraception. Conversely, US regulatory documents state that available data have not identified a drug-associated risk of major adverse outcomes. Use also requires mandatory and regular monitoring of liver function during the course of treatment.

Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Ursidesox (Ursodiol) is structured around the potential for reduced absorption and the modification of other drug exposures.

Interactions Affecting Ursodiol Absorption

The absorption of Ursodiol is reduced by medicinal products that bind bile acids in the intestine. These agents include Bile Acid Sequestering Agents such as Cholestyramine and Colestipol, as well as Aluminum-Based Antacids. Regulatory documents stipulate that these binding agents must be administered at least 2 hours before or after Ursodiol to prevent interference with its absorption and subsequent efficacy.

Pharmacodynamic Counter-Effects

A major pharmacodynamic interaction involves drugs that increase hepatic cholesterol secretion. Estrogens, Oral Contraceptives, and Clofibrate (and related lipid-lowering drugs) may promote cholesterol gallstone formation, which directly counteracts the therapeutic effectiveness of Ursodiol when used for gallstone dissolution. Due to this counter-effect, the use of hormonal oral contraceptives is restricted for women of childbearing potential taking Ursodiol for this specific indication.

Exposure Modification of Co-administered Drugs

Ursodiol can affect the systemic exposure of several co-administered medicines. It has been documented to increase the intestinal absorption of Ciclosporin. Conversely, Ursodiol has been shown to reduce the plasma peak concentrations (Cmax) and AUC of Nitrendipine, and a reduction in the therapeutic effect of Dapsone has also been reported in some cases. Regarding metabolic pathways, regulatory findings confirm that Ursodiol does not have a relevant inductive effect on Cytochrome P450 3A enzymes.

Advertisements

Mechanism of Action

Modulation of Bile Chemistry and Cholesterol Saturation

Ursodeoxycholic acid (UDCA) competitively displaces toxic, hydrophobic bile acids and directly inhibits the secretion of cholesterol from the liver into the bile. This dual action profoundly reduces the cholesterol concentration in the bile fluid, creating a physiological state where precipitated cholesterol solids are prone to chemical dissolution and limits the conditions necessary for further cholesterol precipitation.


Hepatobiliary Cytoprotection and Membrane Stabilization

The mechanism involves cytoprotection by stabilizing the cell membranes of the liver (hepatocytes) and bile ducts (cholangiocytes), especially the mitochondrial membrane. This cellular action suppresses the activation of pro-apoptotic (cell-death) signaling pathways that are normally triggered by the accumulated toxic bile acids, thereby assisting in the preservation of cellular integrity.


Enhancement of Bile Flow (Choleretic Action)

The drug modulates key transport proteins and ion exchangers, such as AE2, in the bile duct cells. This mechanistic engagement enhances the secretion of water and bicarbonate into the bile ducts, leading to a measurable increase in bile volume and flow. This choleretic effect facilitates bile movement and reduces the potential for bile stasis.


Mechanistic Constraints and Specificity

The mechanism is highly specific and only applies to cholesterol-rich gallstones. The mechanism of dissolution does not apply to calcified or pigment stones. Furthermore, for this dissolution mechanism to operate on the gallbladder solids, the cystic duct must be patent (open) to allow the bile containing active UDCA to circulate.

Advertisements

Dosage and Administration Information

General Administration Principles

Ursidesox (Ursodiol) is provided for oral administration across multiple dosage forms, including capsules, tablets (often scored), and a liquid suspension. The general principles of its use are governed by precise dosing formulas that relate the quantity of medicine to a patient’s body weight and the specific condition being addressed.


Labeled Dosing and Scheduling

The daily amount for Primary Biliary Cholangitis (PBC) is typically calculated as a weight-adjusted dose, ranging from 13 to 15 mg per kilogram of body weight per day (mg/kg/day). For gallstone dissolution, a lower weight-adjusted range of 8 to 10 mg/kg/day is generally utilized. The total daily dose is typically administered in divided doses throughout the day, often with the instruction that the medicine be taken with food. In certain regimens, the largest portion of the daily dose may be scheduled for administration in the evening, sometimes at bedtime.


Administration Logistics and Duration

To accommodate the necessary precision, certain solid dose forms are scored and may be halved for adjustment, but any tablet or tablet segment must be swallowed whole and unchewed with water due to taste and formulation requirements. The duration of therapy is not a short-term course; for PBC, treatment is considered long-term, while for gallstone dissolution, therapy is maintained for many months to two years, continuing for approximately three months after radiological confirmation of dissolution. A specific weight-based administration rule (e.g., 20 mg/kg/day) is also defined for pediatric use in conditions such as Cystic Fibrosis associated hepatobiliary disorder in certain regions.

Advertisements

Recent Clinical Evidence

Research Evidence Overview

Evidence for Use in Primary Biliary Cholangitis (PBC)

Research has examined the medicine for use in conditions characterized by fluctuating or episodic manifestations, specifically Primary Biliary Cholangitis (PBC). Studies monitored outcomes related to systemic or functional imbalance, such as changes in key liver enzymes (like Alkaline Phosphatase and transaminases), and major long-term events like the need for a liver transplant or patient outcomes. The studies explored the medicine in adults with different stages of the condition.

Findings describe patterns observed in the studies where trials consistently reported measurement reductions in elevated liver enzyme levels across the observed populations within the intermediate term. When research looked at extended timeframes, findings were mixed regarding major clinical outcomes related to liver transplantation. Longer-term data show patterns related to disease progression in some patients who reached certain biochemical goals early in the study period.

Evidence for Use in Cholesterol Gallstone Dissolution

Studies explored the medicine for dissolving gallstones, which are conditions marked by functional limitations caused by the stones themselves. Research examined the treatment over defined time intervals, primarily measuring the time required for small, non-calcified gallstones to partially or completely dissolve. The populations observed in these studies were often limited to individuals who met specific criteria for stone size and composition.

Research highlights changes measured during the study period, reporting that complete dissolution often appears to require many months of continuous observation. Findings indicate that the observed patterns were closely linked to the size and physical makeup of the gallstones. Studies also monitored outcomes describing episodic or acute changes, specifically tracking the rate of gallstone recurrence after treatment was stopped.

What is Still Uncertain About Ursidesox (Ursodiol)

Evidence highlights what is known — and what is still uncertain across all studied conditions. A key limitation is that for rare and critical events, such as certain adverse outcomes in pregnancy or the avoidance of liver transplantation, the sample sizes were modest, meaning certainty remains low. For patients with PBC who do not appear to show the desired change in liver enzymes, data for certain groups remain insufficient to provide clear management strategies. Research continues to examine which factors are associated with the rate of gallstone recurrence in patients following dissolution.

Key Studies & References

  1. Ursodeoxycholic acid for primary biliary cirrhosis (Cochrane Review)
  2. Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT (NIHR Journals Library)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ursidesox (Ursodiol) (FAQ)


Q: Is Ursidesox the same as the medicine often called UDCA?

A: The active substance in Ursidesox is Ursodeoxycholic acid (UDCA). This substance is also widely known by its generic name, Ursodiol. Therefore, UDCA, Ursodiol, and Ursidesox (the brand name) all refer to the same therapeutic bile acid derivative.


Q: Can taking Ursidesox cause any changes in weight?

A: Official regulatory documents and product information describe the possibility of 'unusual weight gain or loss' as a potential adverse effect. However, the frequency of this effect is often categorized as 'not known,' meaning there is insufficient data to provide a reliable estimate of how often it might occur.


Q: What types of food or drinks are usually mentioned as interacting with Ursidesox?

A: The official interaction profile is primarily concerned with how co-administered medicines may affect Ursidesox. The medicine is generally described in administration principles as being taken with food. Certain medications like hormonal oral contraceptives and some lipid-lowering drugs may counteract the drug's therapeutic effect by promoting the secretion of cholesterol into the bile.


Q: Is it common to have mild diarrhea when first starting Ursidesox?

A: Diarrhea or pasty stools are classified as 'Common' adverse effects, meaning they are reported in 1% to 10% of patients. While regulatory information notes an initial temporary worsening for certain effects (like pruritus) when beginning treatment, it does not explicitly specify this onset pattern for diarrhea.


Q: Does research show Ursidesox is helpful for conditions other than liver or gallbladder issues?

A: The drug is officially approved for Primary Biliary Cholangitis and for dissolving cholesterol gallstones. Its established use in the pediatric population is for hepatobiliary disorders linked to cystic fibrosis. Regulatory authorization focuses specifically on these conditions, and use for other conditions is not formally established in official labeling.


Q: Can people with diabetes safely use Ursidesox?

A: Official safety documents report 'elevated blood glucose' (high blood sugar) as a potential common side effect, which may indicate a metabolic effect. This information suggests that monitoring of blood glucose levels may be appropriate during treatment.


Q: What is the connection between Ursidesox and cholesterol levels?

A: Ursidesox works by chemically altering the composition of bile. It achieves this by reducing the concentration of cholesterol in the bile fluid, primarily by inhibiting the liver's secretion of cholesterol. This process lowers the cholesterol saturation of the bile, which helps dissolve and prevent certain cholesterol-based solids.


Q: Does Ursidesox affect the results of routine blood tests?

A: Yes, official regulatory documents require mandatory and regular monitoring of specific liver function tests. This is because the medicine can alter the values of certain key liver enzymes, such as AST, ALT, gamma-GT, and bilirubin.


Q: Can Ursidesox affect sleep or cause fatigue?

A: Official documents list fatigue as a common potential adverse effect. Insomnia (trouble sleeping) is also listed as a common psychiatric side effect, and headache is reported as a very common side effect.


Q: Is it true that Ursidesox is a naturally occurring substance?

A: The active ingredient, Ursodeoxycholic acid (UDCA), is a type of secondary bile acid that occurs naturally in human bile. However, the medicine used for prescription treatment is a standardized, pharmaceutically manufactured semisynthetic product.


Q: Is Ursidesox a prescription-only medicine?

A: Yes, regulatory records confirm that Ursidesox (Ursodiol) is classified as a prescription-only medicine.


Q: How does Ursidesox compare to other medications that treat gallstones (in terms of class)?

A: Ursidesox is categorized by regulatory bodies as a cholelitholytic agent and a hepatoprotective agent. It belongs to the class of bile acid derivatives. Other medicines used to treat gallstones may belong to the same pharmacological class or have different mechanisms of action.


Q: Can men and women use Ursidesox equally, or are there differences in use?

A: The medication is approved for use in both men and women for its indications. A key difference documented in official information is that women of childbearing potential taking the medicine for gallstone dissolution are required to use non-hormonal contraception, as hormonal contraceptives may counteract the drug's therapeutic effectiveness.


Q: Are there any known issues with drinking alcohol while taking Ursidesox?

A: There is no explicit 'alcohol interaction' contraindication listed in the core regulatory label. General safety information suggests reviewing the use of alcohol with a healthcare professional, particularly as the drug is utilized for conditions affecting the liver and bile system.


Q: What does official research say about the long-term use of Ursidesox?

A: Official product information indicates that treatment for Primary Biliary Cholangitis (PBC) is typically considered long-term. For dissolving gallstones, therapy is maintained for many months to up to two years, often continuing for several months after radiological confirmation of dissolution.


Q: Does Ursidesox have an impact on mood or anxiety?

A: Official safety documentation has reported 'anxiety' and 'depression' as potential psychiatric adverse effects. These reports are sometimes grouped with other Central Nervous System (CNS) effects such as fatigue and insomnia.


Q: Is it safe to drive or operate machinery while taking Ursidesox?

A: Due to the potential for adverse effects such as headache and dizziness, general safety information describes a constraint against driving or operating heavy machinery until the individual is aware of the medicine’s effects.


Q: Do official documents mention any potential for hair loss with Ursidesox?

A: Yes, official documentation has reported alopecia, which is hair thinning or loss, as a common dermatologic adverse event in clinical trials, occurring in 1% to 10% of patients.


Q: Can people with pre-existing kidney issues use Ursidesox?

A: Official information suggests that because the medicine is primarily eliminated through the liver and bile system, the regulatory text does not require dosage changes for kidney impairment. However, closer monitoring of liver and kidney function is commonly described as a clinical practice for individuals with severe renal impairment.

Advertisements

How should Ursidesox (Ursodiol) be stored and disposed of?

Official Storage and Disposal Requirements

Ursodiol (Ursidesox) must be stored and handled according to specific regulatory requirements to maintain its stability and ensure safety.

Storage Conditions

Requirement Standard Mandate
Temperature Store at controlled room temperature, typically 20 C to 25 C.
Protection Keep the medication away from moisture, direct light, and do not freeze.
Container Store in a closed, tightly sealed container. If tablets are broken, segments must be stored separately.
Liquid Form Stability Compounded oral suspensions may require refrigeration and have a limited Beyond-Use Date (BUD).

Safety and Disposal

Regulatory labeling requires that the product must be stored out of the reach and sight of children. Unused or outdated medicine must not be kept. For proper disposal, patients must ask a healthcare professional (pharmacist or doctor) for guidance, as the product should generally not be disposed of in household waste or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ursidesox (Ursodiol) found in:

A-Z Index: